Table 1.
First author Year |
Location | Animal (sex, strain, weight) | Number of each group | Modeling method | Modeling duration | Type and source of MSC | Way of MSC administrated | Times of treatment | Dose of MSC | Parameter |
---|---|---|---|---|---|---|---|---|---|---|
Forte; 2015 [16] | Italy | Male, C57BL/6 mice, NA | DSS + PBS (n = 4) DSS + MSC (n = 4) | DSS (1.5%) | 9 | hASC | Irrigation | 3 | 1 × 106 cells/mouse/time | DAI, HS |
Chao; 2016 [17] | China | Male, BALB/c mice, NA |
TNBS + 50% ethanol + MSC (n = 20) TNBS + 50% ethanol (n = 20) |
TNBS (5%) | 8 | hUC-MSC | Intraperitoneal injection | 1 | 1 × 106 cells/mouse/time | HS, MPO activity |
Gao; 2020 [18] | China | Male, Wistar rat, 150–200 g |
TNBS + 50% ethanol + MSC (n = 8) TNBS + 50% ethanol (n = 8) |
TNBS (2%) | 8 | rASC | Tail vein injection | 1 | 1 × 107 cells/mouse/time | DAI, colon length |
Nam; 2015 [19] | South Korea | Female, C57BL/6, NA |
DSS + PBS (n = 10) DSS + MSC (n = 10) |
DSS (3.5%) | 7 | mBM-MSC | Intraperitoneal injection | 1 | 1 × 106 cells/mouse/time | DAI |
Yang; 2018 [20] | China | Female, C57 mice, 19–21 g |
DSS + PBS (n = 10) DSS + MSC (n = 10) |
DSS (1.5%) | 6 | hUC-MSC | Intraperitoneal injection | 2 | 2 × 106 cells/mouse/time | DAI, HS |
Gonzalez-Rey; 2008 [21] | Spain | NA, C57BI/6 mice, NA |
DSS + PBS (n = 14) DSS + MSC (n = 14) |
DSS (5%) DSS (3%) |
7 34 |
hASC | Intraperitoneal injection |
1 2 |
1 × 106 cells/mouse/time | DAI, colon length, HS, MPO activity |
Lin; 2015 [22] | China | Male, C57BL/6 mice, NA |
DSS + PBS (n = 10) DSS + MSC (n = 10) |
DSS (5%) | 7 | hUC-MSC | Intraperitoneal injection | 1 | 2 × 106 cells/mouse/time | DAI, colon length, MPO activity |
Banerjee; 2015 [23] | Italy | Male, NOD.CB17-Prkdcscid/J mice, 18–25 g |
DSS + PBS (n = 5) DSS + MSC (n = 5) |
DSS (3.5%) | 7 | hUC-MSC | Tail vein injection | 1 | 1 × 106 cells/mouse/time | DAI, colon length, HS, MPO activity |
Song; 2018 [24] | South Korea | Male, C57BL/6 J mice, NA |
DSS + PBS (n = 6) DSS + MSC (n = 6) |
DSS (3%) | 7 | cAT-MSC | Intraperitoneal injection | 1 | 2 × 106 cells/mouse/time | DAI, colon length, HS |
Lim; 2021 [25] | South Korea | Female, C57BL/6 mice, NA |
DSS + PBS (n = 4) DSS + MSC (n = 4) |
DSS (2.5%) | 9 | mBM-MSC | Intraperitoneal injection | 1 | 3 × 106 cells/mouse/time | DAI, colon length |
Miyamoto; 2017 [26] | Japan | Male, Sprague–Dawley rats, NA |
TNBS + 30% ethanol + MSC (n = 9) TNBS + 30% ethanol + PBS (n = 9) |
TNBS (45 mg/kg) | 7 | hAMSC | Penile vein injection | 1 | 1 × 106 cells/mouse/time | HS |
Ikarashi; 2017 [27] | Japan | Male, C57BL/6 mice, NA |
DSS + PBS (n = 7) DSS + MSC (n = 16) |
DSS (2.5%) | 7 |
hASC hUC-MSC |
Intravenous injection | 1 | 1 × 106 cells/mouse/time | DAI, colon length, HS |
Li; 2020 [28] | China | Female, C57BL/6 mice, 18-22 g |
DSS + PBS (n = 12) DSS + MSC (n = 12) |
DSS (3%) |
8 24 |
hUC-MSC | Intraperitoneal injection |
2 4 |
2 × 106 cells/mouse/time | DAI, MPO activity, colon length, HS |
Lee; 2016 [29] | South Korea | Female, C57BL/6 mice, 17-21 g |
DSS + PBS (n = 5) DSS + MSC (n = 5) |
DSS (3%) | 30 | mBM-MSC | Intravenous injection | 3 | 1 × 107 cells/mouse/time | Colon length, HS |
Jo; 2019 [30] | South Korea | Female, C57BL/6 mice, NA |
DSS + PBS (n = 5) DSS + MSC (n = 5) |
DSS (3%) | 20 | mBM-MSC | Intraperitoneal injection | 2 | 1 × 106 cells/mouse/time | Colon length, HS |
Heidari; 2018 [31] | Iran | Female, C57BL/6 mice, 18–22 g |
DSS + PBS (n = 5) DSS + MSC (n = 5) |
DSS (2%) | 33 | mASC | Intraperitoneal injection | 2 | 1 × 106 cells/mouse/time | DAI, colon length, HS |
Kawata; 2019 [32] | Japan | Male, C57BL/6 mice, NA |
DSS + PBS (n = 5) DSS + MSC (n = 7) |
DSS (2.5%) | 7 | hASC | Intravenous injection | 1 | 1 × 106 cells/mouse/time | DAI, colon length, HS |
Yu; 2017 [33] | South Korea | Male, C57BL/6 mice, 18–25 g |
DSS + PBS (n = 9) DSS + MSC (n = 18) |
DSS (1.5%) | 30 | hTMSC | Intraperitoneal injection |
2 4 |
1 × 106 cells/mouse/time | Colon length |
Lu; 2019 [34] | China | NA, C57BL/6 mice, NA |
DSS + PBS (n = 6) DSS + MSC (n = 6) |
DSS (3%) | 26 | hGMSC | Tail vein injection | 1 | NA | Colon length |
Tanaka; 2010 [35] | Japan | NA, Lewis rat, 180–220 g |
DSS + PBS (n = 10) DSS + MSC (n = 10) |
DSS (4%) | 7 | rBM-MSC | Tail vein injection | 3 |
2 × 104 cells/g/time (the second and third injection) 2 × 103 cells/g/time (the first injection) |
HS |
Molendijk; 2016 [36] | The Netherlands | Female, C57BL/6Jico mice, NA |
DSS + PBS (n = 7) DSS + MSC (n = 21) |
DSS (1.25%) | 7 | mBM-MSC | Local injection | 1 |
0.5 × 106 cells/mouse/time 2 × 106 cells/mouse/time |
Colon length |
Liang; 2011 [37] | China | Male, BALB/c mice, 20 g |
TNBS + 50% ethanol + MSC (n = 6) TNBS + 50% ethanol (n = 6) |
TNBS (100 mg/kg) | 5 | hUC-MSC | Intravenous injection | 2 | 1 × 106 cells/mouse/time | HS, MPO activity |
Fuenzali; 2016 [38] | Chile | Female, C57BL/6 mice, NA |
DSS + PBS (n = 7) DSS + MSC (n = 7) |
DSS (2.5%) | 7 | hUC-MSC | Intraperitoneal injection | 2 | 1 × 106 cells/mouse/time | Colon length |
Li; 2013 [39] | China | NA, C57Bl/6 mice, NA |
DSS + PBS (n = 8) DSS + MSC (n = 16) |
DSS (4%) | 7 |
hUC-MSC hBM-MSC |
Intraperitoneal injection | 1 | 1 × 106 cells/mouse/time | HS, colon length, MPO activity |
Tanaka; 2008 [40] | Japan | Male, Lewis rats, approximately 200 g |
DSS + PBS (n = 5) DSS + MSC (n = 5) |
DSS (4%) | 7 | rBM-MSC | Tail vein injection | 1 | 5 × 106 cells/mouse/time | Colon length |
Nikolic; 2018 [41] | Serbia | NA, C57BL/6 mice, 19–21 g |
DSS + PBS (n = 35) DSS + MSC (n = 35) |
DSS (3%) | 7 | mBM-MSC | Tail vein injection | 3 | 2 × 106 cells/mouse/time | HS, colon length |
Nan; 2018 [42] | China | Male, Sprague–Dawley rats, 160–180 g |
TNBS + 50% ethanol + MSC (n = 8) TNBS + 50% ethanol (n = 8) |
TNBS (NA) | 7 | rBM-MSC | Tail vein injection | 1 | 5 × 106 cells/mouse/time | Colon length, HS |
Xie; 2017 [43] | China | NA, BALB/c mice, NA |
TNBS + 50% ethanol + MSC (n = 30) TNBS + 50% ethanol (n = 15) |
TNBS (3%) | 3 |
mBM-MSC mASC |
Intraperitoneal injection | 1 | 1 × 106 cells/mouse/time | HS |
DSS, dextran sodium sulfate; TNBS, trinitrobenzene sulfonic acid; MSC, mesenchymal stem cell; PBS, phosphate buffer saline; hUC-MSC, human umbilical cord MSC; mBM-MSC, murine bone marrow MSC; rBM-MSC, rat bone marrow MSC; hBM-MSC, human bone marrow MSC; hASC, human adipose-derived MSC; mASC, murine adipose-derived MSC; rASC, rat adipose-derived MSC; hTMSC, human tonsil-derived mesenchymal stem cell; hGMSC, human gingiva-derived mesenchymal stem cell; hAMSC, human amnion-derived MSC; cAT-MSC, canine adipose tissue-derived MSC; DAI, disease activity index; HS, histopathological score; MPO, activity myeloperoxidase activity; NA, not available